Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?
James J. Figge,William E. Gooding,David L. Steward,Linwah Yip,Rebecca S. Sippel,Samantha Peiling Yang,Randall P. Scheri,Jennifer A. Sipos,Susan J. Mandel,Sarah E. Mayson,Kenneth D. Burman,Jessica M. Folek,Bryan R. Haugen,Julie A. Sosa,Rajeev Parameswaran,Wee Boon Tan,Yuri E. Nikiforov,Sally E. Carty
DOI: https://doi.org/10.1089/thy.2021.0119
IF: 6.506
2021-11-01
Thyroid
Abstract:Background: Molecular testing (MT) is commonly used to refine cancer probability in thyroid nodules with indeterminate cytology. Whether or not ultrasound (US) patterns and clinical parameters can further inform the risk of thyroid cancer in nodules predicted to be positive or negative by MT remains unknown. Aim: To test if clinical parameters, including patient age, gender, nodule size (by US), Bethesda category (III, IV, V), US pattern (American Thyroid Association [ATA] vs American College of Radiology TI-RADS systems), radiation exposure, or family history of thyroid cancer can modify the probability of thyroid cancer or NIFTP predicted by MT. Methods: We studied 257 thyroid nodules in 232 patients from 10 study centers with indeterminate fine needle aspiration cytology and informative MT results using the ThyroSeq v3 genomic classifier (TSv3). Univariate and multivariate logistic regression were used for data analysis. Results: The presence of cancer/NIFTP was associated with positive TSv3 results (OR 61.39, P<0.0001). On univariate regression, patient gender, age, and Bethesda category were associated with cancer/NIFTP probability (P<0.05 for each). Although ATA (P=0.1211) and TI-RADS (P=0.1359) US categories demonstrated positive trends, neither were significantly associated with cancer/NIFTP probability. A multivariate regression model incorporating the four most informative non-MT covariates (gender, age, Bethesda category, and ATA US pattern) (Model #1) yielded a C index of 0.653; R2=0.108. When TSv3 was added to Model #1, the C index increased to 0.888; R2=0.572. However, age (P=0.341), Bethesda category (P=0.272), and ATA US pattern (P=0.264) were nonsignificant, and other than TSv3 (P<0.0001), male gender was the only non-MT parameter that potentially contributed to cancer/NIFTP risk (P=0.095). The simplest and most efficient clinical model (#3) incorporated TSv3 and gender (C index=0.889; R2=0.588). Conclusions: In this multicenter study of thyroid nodules with indeterminate cytology and molecular testing, neither the ATA nor TI-RADS US scoring systems further informed the risk of cancer/NIFTP beyond that predicted by TSv3. Although age and Bethesda category were associated with cancer/NIFTP probability on univariate analysis, in sequential nomograms they provided limited incremental value above the high predictive ability of TSv3. Patient gender may contribute to cancer/NIFTP risk in thyroid nodules with indeterminate cytology.
endocrinology & metabolism